Background Vitamin K antagonists, such as warfarin, are standard treatments for stroke
prophylaxis in patients with atrial fibrillation. Patient outcomes depend on quality of warfarin …

Background The recent availability of dabigatran, a novel oral anticoagulant, provided a new
treatment option for stroke prevention in atrial fibrillation beyond warfarin, the main therapy …

Background and purpose GLORIA-AF is a large, global, prospective registry program of
newly diagnosed atrial fibrillation (AF) patients with≥ 1 stroke risk factors. We describe the …

Objective Our objective was to assess the cost effectiveness of apixaban versus edoxaban
in the prevention of stroke and systemic embolism (SE) in patients with atrial fibrillation (AF) …

Background and Purpose—To estimate the cost-effectiveness of stroke prevention in
patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg …

Introduction and objectives To assess the cost-effectiveness of edoxaban vs acenocoumarol
in the prevention of stroke and systemic embolism in patients with nonvalvular atrial …

Background Strokes attributed to atrial fibrillation (AF) represent a major cause of adult
disability and a great burden to society and healthcare systems. Objectives Our objective …

Purpose Three new oral anticoagulants (NOACs) have recently become available in the
United Kingdom as an alternative to warfarin in the prevention of stroke and systemic …

Aims Randomized trials showed non-inferior or superior results of the non-vitamin-K-
antagonist oral anticoagulants (NOACs) compared with warfarin. The aim of this study was …

Objective The prevalence of atrial fibrillation (AF) and the risk of stroke and bleeding vary
according to age. To estimate effects of dabigatran, compared with warfarin, on stroke …